Published in Graefes Arch Clin Exp Ophthalmol on July 20, 2013
Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease. Graefes Arch Clin Exp Ophthalmol (2015) 1.08
Pars plana vitrectomy for treatment of advanced Coats' disease--presentation of a modified surgical technique and long-term follow-up. Graefes Arch Clin Exp Ophthalmol (2013) 0.90
Coats' Disease: Very Long-Term Outcome After Early Stage Conventional Treatment. Open Ophthalmol J (2016) 0.77
Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases. BMC Ophthalmol (2014) 0.76
Evaluation of Follow-Up and Treatment Results in Coats' Disease. Turk J Ophthalmol (2016) 0.75
Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol (2001) 3.53
Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol (2007) 2.95
Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol (2001) 2.81
Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol (1995) 2.35
Coats' disease diagnosed in adulthood. Ophthalmology (2005) 1.84
The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina (2010) 1.82
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One (2008) 1.68
Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci (2010) 1.61
Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 1.59
Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol (2008) 1.59
Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol (2011) 1.59
Coats' disease: an Indian perspective. Indian J Ophthalmol (2010) 1.26
Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult Coats' disease: a case report. Korean J Ophthalmol (2010) 1.21
Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol (2010) 1.21
Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res (2012) 1.20
Resolution of macular edema in Coats' disease with intravitreal bevacizumab. Indian J Ophthalmol (2009) 1.17
Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch Ophthalmol (2010) 1.16
Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2010) 1.12
Expression of vascular endothelial growth factor in eyes with Coats' disease. Invest Ophthalmol Vis Sci (2013) 1.09
Treatment of Coats' disease with intravitreal bevacizumab. Br J Ophthalmol (2012) 1.06
Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol (2008) 1.01
Visual prognosis of Coats' disease. J AAPOS (1998) 0.93
Resolution of total retinal detachment in Coats' disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol (2010) 0.83
Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease. J Ocul Pharmacol Ther (2012) 0.82
The effect of bevacizumab on spinal epidural fibrosis in a postlaminectomy rat model. Turk Neurosurg (2012) 0.79
Pars plana vitrectomy in advanced coats' disease. Case Rep Ophthalmol (2011) 0.77
Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes. Retina (2010) 0.77
Proliferative vitreoretinopathy in Coats' disease. Clinicohistopathological case report. Ophthalmologica (1995) 0.75
The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina (2011) 0.75
Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (2010) 0.93
Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol (2011) 0.88
Anatomic evaluation of macular holes with silicone oil tamponades in highly myopic eyes using optical coherence tomography. Eur J Ophthalmol (2010) 0.86
Apelin-13 regulates proliferation, migration and survival of retinal Müller cells under hypoxia. Diabetes Res Clin Pract (2013) 0.83
Resolution of total retinal detachment in Coats' disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol (2010) 0.83
Enhanced dissolution and oral bioavailability of tanshinone IIA base by solid dispersion system with low-molecular-weight chitosan. J Pharm Pharmacol (2013) 0.82
Apelin supports primary rat retinal Müller cells under chemical hypoxia and glucose deprivation. Peptides (2012) 0.82
Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study. Mol Vis (2011) 0.82
Evaluation of an in situ chemically crosslinked hydrogel as a long-term vitreous substitute material. Acta Biomater (2012) 0.81
Multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis after stem-cell transplantation. Graefes Arch Clin Exp Ophthalmol (2013) 0.81
Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization. Mol Vis (2010) 0.81
Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina (2010) 0.80
Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy. Am J Ophthalmol (2011) 0.79
Axial length measurements before and after removal of silicone oil: a new method to correct the axial length of silicone-filled eyes for optical biometry. Ophthalmic Physiol Opt (2009) 0.79
The role of apelin in the retina of diabetic rats. PLoS One (2013) 0.78
Intraocular expression of thymosin β4 in proliferative diabetic retinopathy. Acta Ophthalmol (2011) 0.77
Influential factors of thresholds for electrically evoked potentials elicited by intraorbital electrical stimulation of the optic nerve in rabbit eyes. Vision Res (2007) 0.77
[Preparation of baicalin colon-specific solid dispersion and evaluation on its in vitro release]. Zhongguo Zhong Yao Za Zhi (2014) 0.77
[Studies on sustained release solid dispersion of tripterine carried by HPMC-stearic acid]. Zhongguo Zhong Yao Za Zhi (2012) 0.75
Fundus and histopathological study of radial optic neurotomy in the normal miniature pig eye. Arch Ophthalmol (2005) 0.75
Decreased prothrombin time after intravitreal bevacizumab in the early period in patients with proliferative diabetic retinopathy. Acta Ophthalmol (2011) 0.75
[Advance in studies on phospholipid compound of traditional Chinese medicines]. Zhongguo Zhong Yao Za Zhi (2013) 0.75
[Preparation of baicalin-chitooligosaccharide compound and its characterization]. Zhongguo Zhong Yao Za Zhi (2014) 0.75
Resolution of diabetic papillopathy with a single intravitreal injection of bevacizumab combined with triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol (2013) 0.75
[Effect of spray drying process on physical properties and dissolution of tanshinone]. Zhongguo Zhong Yao Za Zhi (2014) 0.75
[Influence of membrane dissection and en bloc excision on the outcome of vitreous surgery in proliferative diabetic retinopathy]. Zhonghua Yan Ke Za Zhi (2004) 0.75
[Study on Xinyueshu spray drying assisted with copovidone and its effect on powder property]. Zhongguo Zhong Yao Za Zhi (2013) 0.75
Traumatic choriodialysis treated by intraocular fibrin glue. Acta Ophthalmol (2009) 0.75